U.S. drugmaker Pfizer Inc, which has been considering a split into two companies for more than two years, said on Monday it will not do so because the move would not create any shareholder value.
Pfizer will keep its low-growth generics and patent-protected branded medicines separate, giving it the option to split down the road if “factors materially change at some point in the future.”
Pfizer said on Monday the decision would not have an impact on its 2016 financial forecast.
The decision not to create two publicly traded companies follows the collapse of its planned $160 billion acquisition of Allergan Inc after a change in tax law took away the tax benefits of the deal.
Investors were expecting the company to step back from the split, Sanford Bernstein analyst Tim Anderson said in a research note.
“Where to from here? The company seems likely to leave open its option for a future split-up, but more immediately it may continue hunting for M&A targets,” Anderson wrote.
Pfizer’s shares were down 1.2 percent to $33.85 in premarket trading on Monday.
The pharma giant began openly planning for the possible split in early 2014, saying it would operate the businesses as separate divisions and track their progress for three years before reaching a decision. In August, it said a decision would be made by year-end.
Pfizer said the sum-of-the-parts analysis showed no benefit to shareholders, and that tax costs and business disruptions were factors it considered.
The company had considered the move largely because its patent-protected medicines routinely enjoy sales growth while sales in the generics portfolio usually declined.
Investors shifted their focus to whether Pfizer would split after the company terminated the deal for Irish drugmaker Allergan in April.
In August Pfizer announced it was buying cancer drugmaker Medivation Inc for $14 billion to get access to blockbuster prostate cancer drug Xtandi for its growing oncology roster.
The Medivation deal illustrates a shift in Pfizer’s mergers and acquisitions strategy from lowering taxes, which was the rationale behind the failed Allergan tax inversion deal, to strengthening its lineup of branded drugs, especially lucrative cancer treatments.
A year ago, Pfizer paid $15 billion for Hospira, which sells generic hospital products and is developing biosimilars to compete with big-selling injectable biotech drugs. That deal was seen by Wall Street as a way of bolstering its generic drugs operation ahead of potentially divesting the business.
By Natalie Grover and Caroline Humer
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.